P&G Just Put $3.8 Billion Behind the One Story It Has Been Telling All Year

Key Stats for P&G Stock

• Current Price: $142.97
• Target Price (Mid): ~$200
• Street Target: ~$161
• Potential Total Return: ~40%
• Annualized Return: ~7% / year

Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free) >>>

What Happened?

Procter & Gamble (PG) agreed on August 4 to buy supplement maker Thorne for $3.8 billion, and the price tag is the tell. It is the company’s clearest bet yet on premium wellness, and it lands while the stock trades at $142.97, roughly 15% below its 52-week high. Investors searching for the deal want one answer: is P&G buying growth it cannot generate on its own, or finally acting on the health-and-beauty tilt management has described for months?

Shares rose about 1% on the news, then drifted, pressured three days later by an Argus downgrade to Hold. That muted response is the live tension. P&G is making a real move into the fastest-growing corner of its portfolio, yet the stock is priced as though nothing changed. The deal, the downgrade, and a fresh fourth quarter give investors enough to judge whether the reset is working.

Why Thorne Fits the “Bigger More” Playbook

Thorne is a science-backed supplement brand founded in 1984, and its appeal is demographic: roughly 60% of its revenue comes from consumers under 40, with sales shifting fast toward direct-to-consumer channels and annual revenue above $500 million in 2025. P&G is paying $3.8 billion for a business that L Catterton took private for $680 million in 2023, a return of roughly 5.6 times in about three years. That rich price explains the market’s hesitation, and P&G health-care chief Paul Gama framed the deal as a premium wellness purchase, not a bargain. It is expected to close later this year, pending regulatory approval.

CEO Shailesh Jejurikar has argued the next leg of growth comes from higher-growth segments and “bigger more” innovation, telling analysts the U.S. and Europe still hold “$5 billion to $10 billion growth opportunities over the next 3 to 5 years.” Thorne slots into that thesis. It joins a Health Care segment that already houses Metamucil, Align, and New Chapter, and grew to about $12.5 billion in fiscal 2026. That segment sits alongside a Beauty and Skin business that grew mid-single digits for the year and an international arm now inflecting, with China growing share “for the first time in 15 quarters” and SK-II up 8% there, excluding travel retail. Adding a Gen Z and millennial wellness brand to that mix is the portfolio tilt made concrete, and P&G has run this play before: it has owned New Chapter vitamins since 2012 without breaking the brand.

See historical and forward estimates for P&G stock (It’s free!) >>>

The Downgrade That Frames the Bear Case

Three days after Thorne, Argus analyst Chris Graja cut P&G to Hold from Buy. His reasoning is the cleanest version of the skeptical view: core operating margin has fallen for three straight quarters, the stock has trailed both the S&P 500 and the staples sector this year, and management guided fiscal 2027 to slow growth of 1% to 3% on the top line and 0% to 3% on core EPS. Against that, a $3.8 billion deal reads to bears as buying growth the organic business is not producing.

Revenue of $21.20 billion missed the Street by 0.82%, EBIT missed by 2.52%, and organic sales rounded down to flat, with North America down 1% as shipments lagged consumption by 3 points on Prime Day timing and retailer destocking. Adjusted EPS of $1.43 edged past the $1.41 estimate but fell 3% year over year, and management expects first-quarter fiscal 2027 EPS down 5% or more before costs ease.

CFO Andre Schulten guided a fiscal 2027 earnings headwind of roughly $1.4 billion after tax, about $0.56 per share, which combines an approximately $1 billion oil-linked input-cost hit with currency and interest pressure and lands hardest in the first half. He paired that with record cost-of-goods productivity and a U.S. business where the share of top customer-brand combinations growing or holding share improved from under 10% to about 50% across fiscal 2026. If that consumption recovery holds and costs anniversary, margins inflect, and the flat quarters give way to the reacceleration analysts already model.

On valuation, P&G trades near 20 times price-to-earnings on a forward basis, a premium to Kimberly-Clark at about 15 times, and Reckitt Benckiser near 14 times, but a discount to Colgate-Palmolive at roughly 23 times. The premium over the cheaper peers is defensible on a trailing operating margin near 25%, category leadership across most of its ten segments, and the pricing power behind Tide and Pampers.

See how P&G performs against its peers in TIKR (It’s free!) >>>

TIKR Advanced Model Analysis

• Current Price: $142.97
• Target Price (Mid): ~$200
• Potential Total Return: ~40%
• Annualized Return: ~7% / year

See analysts’ growth forecasts and price targets for P&G stock (It’s free!) >>>

TIKR’s mid-case model values P&G at around $200 per share, realized by mid-2031, a total return near 40% from today’s price, or roughly 7% annualized over 4.9 years. That is a steady-compounder return, not a re-rating, leaning on earnings growth and P&G’s 70-year dividend-increase streak rather than multiple expansion; the model assumes the P/E drifts slightly lower.

• Revenue drivers: the Beauty and Skin segment, now reinforced by the wellness portfolio, and international Enterprise Markets, which grew 4% in fiscal 2026 led by Latin America at 6%.
• Margin driver: operating leverage from the productivity program, with the mid-case assuming net income margins near 19%.
• Primary risk: the fiscal 2027 cost headwind, which hits hardest early and could push margins lower before they recover.
• Upside: the U.S. consumption recovery converts to sustained share growth as costs ease, lifting the stock above the mid-case target.
• Downside: a prolonged oil shock keeps input costs high, and consumer demand soft, stalling the stock near current levels while the dividend does the work.

Conclusion

The Thorne deal will not close for months and is small against P&G’s $87 billion base, so it will not move fiscal 2027 numbers. What it signals is where management is spending its conviction. The nearest test comes with first-quarter fiscal 2027 earnings, expected in late October. Watch two things: whether North America organic sales turn positive as the shipment-consumption gap closes, and whether core operating margin stops falling after three down quarters. Positive U.S. organic growth with stabilizing margins confirms the reset is real. Another flat quarter with margins still sliding hands the bears a fourth data point, and the Thorne premium starts to look like a distraction.

See what stocks billionaire investors are buying so you can follow the smart money with TIKR.

Should You Invest in P&G?

The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.

Pull up P&G, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.

You can build a free watchlist to track P&G alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.

Analyze P&G on TIKR Free →

Looking for New Opportunities?

Disclaimer:

Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!